SCHEDULE: Alumni Capital Discloses 9.99% Stake in Kazia Therapeutics

Alumni Capital LP and its affiliates have disclosed a 9.99% beneficial ownership stake in Kazia Therapeutics Limited through various purchase agreements and warrants.

Summary

• Alumni Capital LP, Alumni Capital GP LLC, and Ashkan Mapar (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G for Kazia Therapeutics Limited.
• The Reporting Persons beneficially own 178,591 American Depository Shares (ADSs), representing 9.99% of the class.
• This ownership includes 28,409 ADSs currently held as of the filing date, along with ADSs that may be acquired through a Purchase Agreement dated April 19, 2024, Commitment Warrants, Common Warrants dated January 10, 2025, and a Securities Purchase Agreement dated July 31, 2025.
• A key limitation prohibits the Reporting Persons from exceeding 9.99% beneficial ownership of Kazia Therapeutics' outstanding shares.
• The percentage is calculated based on 1,609,108 ADSs outstanding as of July 25, 2025, as represented in the Issuer's prospectus supplement, plus the approximate total number of shares the Reporting Persons may acquire subject to the ownership limitation.

Sentiment

Score: 7

Explanation: The disclosure of a significant, albeit passive, institutional stake by Alumni Capital LP in Kazia Therapeutics is generally a positive signal for the company, indicating investor interest and potential for future capital infusion through the mentioned agreements and warrants.

Positives

• A significant institutional investor, Alumni Capital LP, has taken a substantial stake, potentially signaling confidence in Kazia Therapeutics' future prospects.
• The investment is structured with an ownership limitation, indicating a passive investment rather than an attempt to control the company, which can be viewed favorably by existing management and shareholders.

Risks

• The beneficial ownership reported includes shares that may be acquired through warrants and purchase agreements, meaning the full 9.99% stake is not yet fully realized and depends on future actions or the issuer's discretion.
• The 9.99% "Ownership Limitation" restricts further accumulation of shares by Alumni Capital and its affiliates, potentially capping their influence or investment size in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a near-10% stake could be seen as a vote of confidence, potentially stabilizing or positively influencing the share price. The existence of purchase agreements and warrants suggests potential future capital for the company, which could dilute existing shareholders if new shares are issued, but also provides necessary funding.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a substantial stake in Kazia Therapeutics, which is generally a positive sign of confidence. However, this is a disclosure of ownership and potential future acquisitions via warrants and purchase agreements, not a performance update. While the investment provides potential capital, the full impact on the company's valuation and future performance is not detailed. Therefore, a 'hold' recommendation is appropriate as investors should await further operational or financial updates from Kazia Therapeutics to make a more informed decision, while acknowledging the positive signal from this institutional investment.

Keywords

Kazia Therapeutics, Alumni Capital, Schedule 13G, Beneficial Ownership, American Depository Shares, ADSs, Institutional Investment, Equity Stake, Warrants, Securities Purchase Agreement